ITGB4-targeted therapy might represent a resort to Cetuximab resistance using either antagonizing antibodies as presented here or immunomodulatory approaches including ITGB4-primed dendritic cells or bispecific antibodies targeting T cells and ITGB4-positive tumor cells [44]. The gene discussed is ITGB4; the disease is neoplasm.